John Borgeson

Senior Vice President and Chief Financial Officer at Kodiak Sciences - Palo Alto, California, US

John Borgeson's Colleagues at Kodiak Sciences
Jason Ehrlich

Chief Medical Officer and Chief Development Officer

Contact Jason Ehrlich

Lennard Hachmann

Senior Director Project, Program, and Portfolio Management

Contact Lennard Hachmann

Jonathan Kim

Director Corporate Development

Contact Jonathan Kim

Igor Tarnikov

Senior Director, Digital Health

Contact Igor Tarnikov

Cindy Ressi

Manager, Business Operations

Contact Cindy Ressi

Andreas Zurbriggen

Senior Director, Drug Substance Development and Manufacturing

Contact Andreas Zurbriggen

Fernando Correa

Senior Director, Discovery Medicine

Contact Fernando Correa

View All John Borgeson's Colleagues
John Borgeson's Contact Details
HQ
(650) 281-0850
Location
Company
Kodiak Sciences
John Borgeson's Company Details
Kodiak Sciences logo, Kodiak Sciences contact details

Kodiak Sciences

Palo Alto, California, US • 105 Employees
BioTech/Drugs

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. WORKING AT KODIAK We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you! Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.

Ksi 301 Kodiak Science Kodiak Felix James Baker Ph.D. Kodiak Sciences
Details about Kodiak Sciences
Frequently Asked Questions about John Borgeson
John Borgeson currently works for Kodiak Sciences.
John Borgeson's role at Kodiak Sciences is Senior Vice President and Chief Financial Officer.
John Borgeson's email address is ***@kodiak.com. To view John Borgeson's full email address, please signup to ConnectPlex.
John Borgeson works in the BioTech/Drugs industry.
John Borgeson's colleagues at Kodiak Sciences are Jason Ehrlich, Lennard Hachmann, Jonathan Kim, Igor Tarnikov, Cindy Ressi, Andreas Zurbriggen, Fernando Correa and others.
John Borgeson's phone number is (650) 281-0850
See more information about John Borgeson